Abstract
Hepatectomy is currently routinely performed in most hospitals in China. China owns the largest population of liver diseases and the biggest number of liver resection cases. A nationwide multicenter retrospective investigation involving 112 hospitals was performed, and focused on liver resection for patients with hepatocellular carcinoma (HCC). 42,573 cases of hepatectomy were enrolled, and 18,275 valid cases of liver resection for HCC patients were selected for statistical analysis. The epidemiology of HCC, distribution of hepatectomy, postoperative complications and prognosis were finally analyzed. In the 18,275 HCC patients, 81% had hepatitis B virus infection and 10% had hepatitis C virus infection. 38% of the HCC patients had normal Alphafetoprotein (AFP) level, and other 35% had an AFP level lower than 400 ng mL−1. In the study period, 97% of the hepatectomy for HCC were treated with open surgery, and 23.81% had vascular exclusion techniques. The operation time was (191.7±105.6) min, the blood loss was (546.0±562.8) mL, and blood transfusion was (543.0±1,035.2) mL. The median survival for HCC patients was 631 days, with 1-, 3-, and 5-year overall survival of 73.2%, 28.8% and 19.6%, respectively. Liver cirrhosis, multiple nodules, tumor thrombosis and high AFP level were risk factors that affect postoperative survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Association, S.B.o.t.C.M. (2013). Expert consensus for laparoscopic liver resection (version 2013). Chin J Clin Oncol 40, 303–307.
Association, S.B.o.t.C.M. (2017). Expert consensus on the option of surgical management of hepatocelluar carcinoma (2016 3rd version). Chin J Dig Surg 2017, 113–115.
Balzan, S., Belghiti, J., Farges, O., Ogata, S., Sauvanet, A., Delefosse, D., and Durand, F. (2005). The “50-50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 242, 824–828, discussion 828–829.
Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K., Christensen, E., Pagliaro, L., Colombo, M., Rodés, J., and EASL Panel of Experts on HCC. (2001). Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35, 421–430.
Bruix, J., Sherman, M., and Sherman, M. (2011). Management of hepatocellular carcinoma: an update. Hepatology 53, 1020–1022.
Chen, X.P. (1994). Experience in treatment of huge hepatic cancer by hepatectomy. J Hepatob Surg 2, 193–194.
Chen, X.P., Wu, Z.D., Huang, Z.Y., and Qiu, F.Z. (2005). Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg 92, 334–339.
Chen, X.P., Qiu, F.Z., Wu, Z.D., Zhang, Z.W., Huang, Z.Y., and Chen, Y.F. (2006a). Long-term outcome of resection of large hepatocellular carcinoma. Br J Surg 93, 600–606.
Chen, X.P., Qiu, F.Z., Wu, Z.D., Zhang, Z.W., Huang, Z.Y., Chen, Y.F., Zhang, B.X., He, S.Q., and Zhang, W.G. (2006b). Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 13, 940–946.
Chen, X.P., and Zhang, Z.W. (2017). Interpretation of “Expert consensus on the option of surgical management of hepatocelluar carcinoma” (in Chinese). Chin J Surg 55, 7–10.
Dindo, D., Demartines, N., and Clavien, P.A. (2004). Classification of surgical complications. Ann Surg 240, 205–213.
Goodman, Z.D. (2007). Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 47, 598–607.
Haga, Y., Ikejiri, K., Wada, Y., Takahashi, T., Ikenaga, M., Akiyama, N., Koike, S., Koseki, M., and Saitoh, T. (2011). A multicenter prospective study of surgical audit systems. Ann Surg 253, 194–201.
Hanazaki, K., Kajikawa, S., Shimozawa, N., Mihara, M., Shimada, K., Hiraguri, M., Koide, N., Adachi, W., and Amano, J. (2002). Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma11No competing interests declared. J Am College Surgeons 191, 381–388.
Jarnagin, W.R., Gonen, M., Fong, Y., DeMatteo, R.P., Ben-Porat, L., Little, S., Corvera, C., Weber, S., and Blumgart, L.H. (2002). Improvement in perioperative outcome after hepatic resection. Ann Surg 236, 397–407.
Lai, C.L., Ratziu, V., Yuen, M.F., and Poynard, T. (2003). Viral hepatitis B. Lancet 362, 2089–2094.
Lau, W.Y. (2002). Management of hepatocellular carcinoma. J Royal College Surgeons Edinburgh 47, 389–399.
Lau, W.Y., and Lai, E.C. (2008). Hepatocellular carcinoma: current management and recent advances. Hepatob Pancreat Dis Int 7, 237–257.
Llovet, J.M., Brú, C., and Bruix, J. (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19, 329–338.
Luo, X., Zhang, B., Dong, S., Zhang, B., and Chen, X. (2015). Hepatocellular carcinoma with tumor thrombus occupying the right atrium and portal vein. Medicine 94, e1049.
Papatheodoridis, G.V., Chan, H.L.Y., Hansen, B.E., Janssen, H.L.A., and Lampertico, P. (2015). Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 62, 956–967.
Pugh, R.N.H., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., and Williams, R. (1973). Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60, 646–649.
Vauthey, J.N., Abdalla, E.K., Doherty, D.A., Gertsch, P., Fenstermacher, M. J., Loyer, E.M., Lerut, J., Materne, R., Wang, X., Encarnacion, A., Herron, D., Mathey, C., Ferrari, G., Charnsangavej, C., Do, K.A., and Denys, A. (2002). Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 8, 233–240.
Xiao, H., Zhang, B., Mei, B., Zuo, C., Wei, G., Wang, R., Zhang, B., and Chen, X. (2015). Hepatic resection for hepatocellular carcinoma in patients with portal hypertension. Medicine 94, e495.
Zhang, B., Xu, D., Wang, R., Zhu, P., Mei, B., Wei, G., Xiao, H., Zhang, B., and Chen, X. (2015). Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. Int J Surg 15, 1–5.
Zhang, B., Dong, W., Luo, H., Zhu, X., Chen, L., Li, C., Zhu, P., Zhang, W., Xiang, S., Zhang, W., Huang, Z., and Chen, X.P. (2016). Surgical treatment of hepato-pancreato-biliary disease in China: the Tongji experience. Sci China Life Sci 59, 995–1005.
Acknowledgements
This work was supported by the State Key Project on Inflectional Disease of China (2012ZX10002016-004, 2012ZX 10002010-001-004), the Chinese Ministry of Public Health for Key Clinical Projects (439, 2010) to Prof. Xiaoping Chen, and the National Natural Science Foundation of China (81502524) to Dr. Binhao Zhang.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Zhang, B., Zhang, B., Zhang, Z. et al. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation. Sci. China Life Sci. 61, 660–670 (2018). https://doi.org/10.1007/s11427-017-9259-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-017-9259-9